BR112022027086A2 - Inibidores de irak4 e usos tópicos dos mesmos - Google Patents

Inibidores de irak4 e usos tópicos dos mesmos

Info

Publication number
BR112022027086A2
BR112022027086A2 BR112022027086A BR112022027086A BR112022027086A2 BR 112022027086 A2 BR112022027086 A2 BR 112022027086A2 BR 112022027086 A BR112022027086 A BR 112022027086A BR 112022027086 A BR112022027086 A BR 112022027086A BR 112022027086 A2 BR112022027086 A2 BR 112022027086A2
Authority
BR
Brazil
Prior art keywords
irak4 inhibitors
topical uses
relates
irak4
topical
Prior art date
Application number
BR112022027086A
Other languages
English (en)
Portuguese (pt)
Inventor
L Harden Jamie
Imbert Delphine
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of BR112022027086A2 publication Critical patent/BR112022027086A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
BR112022027086A 2020-06-30 2021-06-29 Inibidores de irak4 e usos tópicos dos mesmos BR112022027086A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046531P 2020-06-30 2020-06-30
PCT/US2021/039646 WO2022006129A1 (en) 2020-06-30 2021-06-29 Irak4 inhibitors and topical uses thereof

Publications (1)

Publication Number Publication Date
BR112022027086A2 true BR112022027086A2 (pt) 2023-03-14

Family

ID=79315566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022027086A BR112022027086A2 (pt) 2020-06-30 2021-06-29 Inibidores de irak4 e usos tópicos dos mesmos

Country Status (9)

Country Link
US (1) US20230390265A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172163A4 (cg-RX-API-DMAC7.html)
JP (1) JP7813733B2 (cg-RX-API-DMAC7.html)
CN (1) CN116134038A (cg-RX-API-DMAC7.html)
AU (1) AU2021300110A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022027086A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186630A1 (cg-RX-API-DMAC7.html)
IL (1) IL298929A (cg-RX-API-DMAC7.html)
WO (1) WO2022006129A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159624A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101741294B1 (ko) * 2010-05-28 2017-05-29 히사미쓰 세이야꾸 가부시키가이샤 미소 돌기가 형성된 어레이를 갖는 디바이스
CA2929316C (en) * 2013-11-08 2021-12-28 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
TW201825095A (zh) * 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
WO2018129364A1 (en) * 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2019143971A2 (en) * 2018-01-18 2019-07-25 Sienna Biopharmaceuticals, Inc. Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
KR20200138730A (ko) * 2018-03-29 2020-12-10 루모사 테라퓨틱스 캄파니 리미티드 가려움증 치료용 조성물 및 방법
US20210260055A1 (en) * 2018-06-21 2021-08-26 Dermavant Sciences GmbH Topical formulations of dgat1 inhibitors and their methods of use
US20200038392A1 (en) * 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
CA3159624A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Also Published As

Publication number Publication date
JP2023540664A (ja) 2023-09-26
EP4172163A4 (en) 2024-07-24
CA3186630A1 (en) 2022-01-06
IL298929A (en) 2023-02-01
EP4172163A1 (en) 2023-05-03
AU2021300110A1 (en) 2023-02-02
US20230390265A1 (en) 2023-12-07
WO2022006129A1 (en) 2022-01-06
JP7813733B2 (ja) 2026-02-13
CN116134038A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
BR112022015110A2 (pt) Compostos e usos dos mesmos
BR112022015109A2 (pt) Compostos e usos dos mesmos
BR112022014949A2 (pt) Compostos e usos dos mesmos
JOP20230190A1 (ar) مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس
CL2024001964A1 (es) Compuestos para la inhibición de nlrp3 y usos de estos
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CL2022000751A1 (es) Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419)
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2021008751A (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
CL2024000239A1 (es) Derivados de piridina sustituida como inhibidores de sarm1
MX2022001123A (es) Inhibidor de pd-1 para usarse en el tratamiento de cancer de piel.
BR112023020781A2 (pt) Moduladores de cbl-b e usos dos mesmos
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
EP4003299A4 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
BR112023019211A2 (pt) Inibidores de inflamassoma nlrp3
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112017025263A2 (pt) método para o tratamento de doença neurológica
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
EP4297765A4 (en) COMPOSITION FOR THE TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONS